Lipidover (Rosuvastatin Calcium)

Rosuvastatin calcium blocks the HMG‑CoA reductase enzyme in the liver, which is essential for cholesterol production. This inhibition reduces the amount of cholesterol made by the liver, leading to increased expression of LDL receptors and enhanced removal of LDL‑cholesterol from the bloodstream.

The specific dose of Lipidover is determined by the prescribing clinician based on the patient’s lipid profile, cardiovascular risk, age, and renal or hepatic function. Typical starting doses range from low to moderate strengths, with adjustments made according to therapeutic response and tolerability.

Safety of rosuvastatin calcium in pregnancy and lactation has not been established. It is generally avoided in pregnant or nursing women unless the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified health professional.

To order Lipidover, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lipidover (rosuvastatin) is a high‑potency statin that often achieves greater LDL‑cholesterol reductions at lower doses compared with older agents such as simvastatin or pravastatin. Its pharmacokinetic profile includes a longer half‑life and minimal metabolism by CYP3A4, which can reduce certain drug‑interaction risks.

Store Lipidover tablets at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Lipidover is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and not split, crush, or chew the tablet unless instructed otherwise.

The most serious adverse events associated with Lipidover include rhabdomyolysis (severe muscle breakdown), significant elevations in liver enzymes indicating hepatic injury, and rare severe allergic reactions such as anaphylaxis. Patients should report unexplained muscle pain, weakness, dark urine, or signs of liver dysfunction promptly.

Lipidover should be avoided in individuals with active liver disease, unexplained persistent elevations of transaminases, known hypersensitivity to rosuvastatin or any component of the formulation, and in patients who are pregnant or breastfeeding unless the benefits outweigh the risks. Caution is also advised for those with severe renal impairment.